The Technical Analyst
Select Language :
Agios Pharmaceuticals Inc [AGIO]

Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology

Agios Pharmaceuticals Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: BUY (auto-tracking)

Agios Pharmaceuticals Inc is listed at the NASDAQ Exchange

3.95% $29.74

Last updated: 8 aug 2022 - 0:36

TimeZone: America/New_York


FUNDAMENTALS
MarketCap: 1 630.29 mill
EPS: -6.43
P/E: 0.000
Earnings Date: Nov 01, 2022
SharesOutstanding: 54.82 mill
Avg Daily Volume: 0.731 mill
RATING 2022-08-05
B+
Buy
RATINGDETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
1/212/213/214/211/222/22
Revenuen/an/an/a
Gr.Profitn/an/an/a
Ebit
Asset
Debt
DISCOUNTED CASH FLOW VALUE
$32.68
(9.90%) $2.94
Date: 2022-08-08
Expected Trading Range (DAY)

$ 28.11 - 31.37

( +/- 5.47%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2022-06-21 Scadden David Buy 29 307 Stock options (right to buy)
2022-06-21 Scadden David Buy 4 975 Restricted stock unit
2022-06-21 Schenkein David P Buy 29 307 Stock options (right to buy)
2022-06-21 Schenkein David P Buy 4 975 Restricted stock unit
2022-06-21 Maraganore John Buy 29 307 Stock options (right to buy)
INSIDER POWER
72.30
Last 100 transactions
Buy: 770 599 | Sell: 106 119

Forecast: 16:00 - $29.74

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $29.74
Forecast 2: 16:00 - $29.74
Forecast 3: 16:00 - $29.74
SCORE
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $29.74 (3.95% )
Volume 1.056 mill
Avg. Vol. 0.731 mill
% of Avg. Vol 144.52 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Agios Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Agios Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Agios Pharmaceuticals Inc

Last 10 Buy & Sell Signals For AGIO

101 Signals | Accuracy: 18.81% | Accuracy Buy: 28.00% | Accuracy Sell: 9.80%

Avg return buy: 0.44 % | Avg return sell: 0.36 %

$1 invested is now $1.23 or 22.86% since 25-07-22

Date Signal @ Closed %
Aug 5 - 15:44buy$29.88N/AActive
Aug 5 - 15:37sell$29.84$29.88 @ Aug 5 - 15:440.13%
Aug 5 - 15:36buy$29.87$29.84 @ Aug 5 - 15:37-0.10%
Aug 5 - 15:34sell$29.85$29.87 @ Aug 5 - 15:360.07%
Aug 5 - 15:21buy$29.91$29.85 @ Aug 5 - 15:34-0.18%
Aug 5 - 15:19sell$29.81$29.91 @ Aug 5 - 15:210.32%
Aug 5 - 15:16buy$29.90$29.81 @ Aug 5 - 15:19-0.28%
Aug 5 - 15:15sell$29.82$29.90 @ Aug 5 - 15:160.27%
Aug 5 - 15:12buy$29.84$29.82 @ Aug 5 - 15:15-0.08%
Aug 5 - 15:01sell$29.83$29.84 @ Aug 5 - 15:120.05%
The Live Chart for Agios Pharmaceuticals Inc
Profile picture for
            Agios Pharmaceuticals Inc

AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Last 10 Buy Signals
Date Signal @
BLOCKUSDAug 8 - 00:340.216
DGDUSDAug 8 - 00:34246.35
GNOUSDAug 8 - 00:34163.82
PIVXUSDAug 8 - 00:340.173
LTCUSDAug 8 - 00:3461.33
PIVXUSDAug 8 - 00:340.173
BCHUSDAug 8 - 00:34141.60
WAVESUSDAug 8 - 00:346.20
ZENUSDAug 8 - 00:3419.45
EOSUSDAug 8 - 00:341.244

Stock Peers

Company Price Change
AGIO29.743.95%
ADPT11.450.79%
ALLO15.465.03%
CELU3.027.86%
INVA14.440.91%
NGM16.154.87%
OM19.081.54%
RDNT20.70-0.19%
RXDX48.005.31%
SLGC5.092.21%
TIL6.384.25%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.